Zarontin Shortage Update: What Patients Need to Know in 2026

If you've had trouble filling your Zarontin prescription lately, you're probably wondering: is there an official shortage? The answer is nuanced—and knowing the real picture can help you take the right steps.

Is Zarontin in an Official FDA Shortage in 2026?

As of early 2026, Zarontin (ethosuximide) is not listed on the FDA or ASHP official drug shortage databases. However, that does not mean it is easy to find. Many patients across the country are reporting difficulty filling their prescriptions, with some pharmacies telling them ethosuximide is backordered or not available for weeks.

This situation—where a drug is technically not in a formal shortage but functionally unavailable at many pharmacies—is sometimes called a "functional shortage" or "supply chain disruption." For patients who depend on Zarontin for seizure control, the end result is the same.

Why Does Zarontin Have Supply Problems?

Several factors contribute to the ongoing availability challenges with Zarontin:

• Limited manufacturers: Only a handful of companies produce generic ethosuximide capsules. Pfizer produces the brand-name Zarontin oral solution. With so few producers, any disruption in manufacturing causes widespread supply problems.
• Low commercial incentive: Ethosuximide treats a relatively rare condition (absence epilepsy), meaning the market is too small to attract many pharmaceutical manufacturers. This structural problem isn't going away.
• Wholesaler allocation: When supply is tight, distributors prioritize their highest-volume pharmacy customers. Independent pharmacies and rural areas often get stock last.
• Low stocking rates at retail pharmacies: Because relatively few patients are prescribed Zarontin compared to medications like antidepressants or blood pressure drugs, many chain pharmacies don't keep it in stock. It is a special-order item at most large chains.

Historical Context: Have There Been Zarontin Shortages Before?

Zarontin has experienced intermittent supply disruptions historically. Epilepsy advocacy organizations have previously highlighted ethosuximide as one of the epilepsy medications affected by supply problems. Industry consolidation among generic pharmaceutical manufacturers in the 2010s and 2020s reduced the number of ethosuximide producers, worsening the vulnerability of the supply chain.

While no prolonged nationwide shortage has occurred as of 2026, intermittent regional and pharmacy-level stockouts have become increasingly common.

What Patients Should Do Right Now

1. Use medfinder — medfinder.com calls pharmacies near you to find which ones currently have Zarontin in stock, saving you hours of phone calls.
2. Ask about both formulations — Zarontin comes as 250 mg capsules and as a 250 mg/5 mL oral solution. One may be available when the other is not.
3. Refill early — Request refills 1 to 2 weeks before running out to give pharmacies time to order it.
4. Try independent pharmacies — They are often more willing and able to special-order ethosuximide than large chain pharmacies.
5. Contact your neurologist if supply runs low — Your neurologist can help coordinate a bridge prescription or alternative if Zarontin is unavailable. Never stop ethosuximide abruptly.

What About the Cost?

Cash price for Zarontin without insurance ranges from $200 to $580 per month. With discount cards like GoodRx or SingleCare, generic ethosuximide can be obtained for as low as $33–$36. Most commercial insurance plans cover generic ethosuximide as a Tier 1 or Tier 2 preferred generic without prior authorization. Pfizer's RxPathways program (1-844-989-7284) may provide assistance to uninsured or government-insured patients who qualify.

Are There New Medications Approved for Absence Seizures?

As of 2026, no new medications have been specifically FDA-approved for absence seizures. Ethosuximide remains the first-line agent, with valproic acid and lamotrigine as established alternatives. Research into novel T-type calcium channel modulators is ongoing, but none have reached approval status.

The Bottom Line

Zarontin is not in a formal FDA shortage as of 2026, but functional availability problems at many pharmacies are real and ongoing. Plan ahead, use medfinder to find stock, and work closely with your neurologist if supply runs out. For information on what to do if Zarontin is unavailable, see our guide on alternatives to Zarontin.